DRI Capital Completes C$600M in Deals in 2012

DRI Capital, a Canadian private equity firm specializing in monetizing royalties it purchases from pharmaceutical and biotechnology companies and others, completed over C$600 million in deals in 2012. Among the firm’s disclosed transactions was the September 2012 acquisition of BENLYSTA royalty rights from Weston, Mass.-based Biogen Idec Ltd. DRI Capital, which celebrates its 20th anniversary in 2013, raised its last partnership, Drug Royalty Fund II, totaling C$700 million, in 2010.

DRI Capital Closes Second Drug Royalty Fund

DRI Capital, a private equity firm which invests in drug royalty streams, has closed its second fund with $701 million in capital commitments. It originally targeted $500 million, with Atlantic-Pacific Capital serving as placement agent.

DRI Crosses Fundraising Target, Doesn’t Stop

DRI Capital, a private equity firm which invests in drug royalty streams, has raised $600 million for its second fund, a source familiar with the situation said. The firm originally targeted $500 million for Drug Royalty II LP, but has continued to accept new commitments. DRI Capital’s first fund was a 2006 vintage with $800 […]

PEHUB Community

Join the 12501 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget